These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38886578)

  • 1. Egr2 to the rescue: nanoparticles revitalize natural killer cells in the fight against cancer.
    Pfefferle A; Phuyal S; Netskar H; Malmberg KJ
    EMBO J; 2024 Jul; 43(13):2527-2529. PubMed ID: 38886578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysfunctional natural killer cells can be reprogrammed to regain anti-tumor activity.
    Sabag B; Puthenveetil A; Levy M; Joseph N; Doniger T; Yaron O; Karako-Lampert S; Lazar I; Awwad F; Ashkenazi S; Barda-Saad M
    EMBO J; 2024 Jul; 43(13):2552-2581. PubMed ID: 38637625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The gene encoding early growth response 2, a target of the transcription factor NFAT, is required for the development and maturation of natural killer T cells.
    Lazarevic V; Zullo AJ; Schweitzer MN; Staton TL; Gallo EM; Crabtree GR; Glimcher LH
    Nat Immunol; 2009 Mar; 10(3):306-13. PubMed ID: 19169262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-17-5p inhibits thyroid cancer progression by suppressing Early growth response 2 (EGR2).
    Geng X; Sun Y; Fu J; Cao L; Li Y
    Bioengineered; 2021 Dec; 12(1):2713-2722. PubMed ID: 34130587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of early growth response 2 expression by secreted frizzled related protein 1.
    Gregory KJ; Morin SM; Schneider SS
    BMC Cancer; 2017 Jul; 17(1):473. PubMed ID: 28687085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early growth response 2 (Egr2) plays opposing roles in committing C3H10T1/2 stem cells to adipocytes and smooth muscle-like cells.
    Wang SS; Huang HY; Chen SZ; Li X; Liu Y; Zhang WT; Tang QQ
    Int J Biochem Cell Biol; 2013 Aug; 45(8):1825-32. PubMed ID: 23751188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered nanoparticles to enhance natural killer cell activity towards onco-immunotherapy: a review.
    Phung CD; Tran TH; Kim JO
    Arch Pharm Res; 2020 Jan; 43(1):32-45. PubMed ID: 31993969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 + T cells.
    Symonds ALJ; Miao T; Busharat Z; Li S; Wang P
    Cancer Immunol Immunother; 2023 May; 72(5):1139-1151. PubMed ID: 36342511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated and sustained expression of the transcription factors Egr1 and Egr2 controls NKT lineage differentiation in response to TCR signaling.
    Seiler MP; Mathew R; Liszewski MK; Spooner CJ; Barr K; Meng F; Singh H; Bendelac A
    Nat Immunol; 2012 Feb; 13(3):264-71. PubMed ID: 22306690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Egr2 induced during DC development acts as an intrinsic negative regulator of DC immunogenicity.
    Miah MA; Byeon SE; Ahmed MS; Yoon CH; Ha SJ; Bae YS
    Eur J Immunol; 2013 Sep; 43(9):2484-96. PubMed ID: 23716134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The transcription factor EGR2 is the molecular linchpin connecting STAT6 activation to the late, stable epigenomic program of alternative macrophage polarization.
    Daniel B; Czimmerer Z; Halasz L; Boto P; Kolostyak Z; Poliska S; Berger WK; Tzerpos P; Nagy G; Horvath A; Hajas G; Cseh T; Nagy A; Sauer S; Francois-Deleuze J; Szatmari I; Bacsi A; Nagy L
    Genes Dev; 2020 Nov; 34(21-22):1474-1492. PubMed ID: 33060136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell-Intrinsic Dysfunction.
    Jung IY; Bartoszek RL; Rech AJ; Collins SM; Ooi SK; Williams EF; Hopkins CR; Narayan V; Haas NB; Frey NV; Hexner EO; Siegel DL; Plesa G; Porter DL; Cantu A; Everett JK; Guedan S; Berger SL; Bushman FD; Herbst F; Fraietta JA
    Cancer Discov; 2023 Jul; 13(7):1636-1655. PubMed ID: 37011008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Egr2 regulation in T cells is mediated through IFNγ/STAT1 and IL-6/STAT3 signalling pathway.
    Taefehshokr N; Miao T; Symonds ALJ; Wang P; Li S
    Pathol Res Pract; 2020 Dec; 216(12):153259. PubMed ID: 33099163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGR1, EGR2, and EGR3 activate the expression of their coregulator NAB2 establishing a negative feedback loop in cells of neuroectodermal and epithelial origin.
    Kumbrink J; Kirsch KH; Johnson JP
    J Cell Biochem; 2010 Sep; 111(1):207-17. PubMed ID: 20506119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Egr2 and 3 Inhibit T-bet-Mediated IFN-γ Production in T Cells.
    Singh R; Miao T; Symonds ALJ; Omodho B; Li S; Wang P
    J Immunol; 2017 Jun; 198(11):4394-4402. PubMed ID: 28455436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An EGR2/CITED1 transcription factor complex and the 14-3-3sigma tumor suppressor are involved in regulating ErbB2 expression in a transgenic-mouse model of human breast cancer.
    Dillon RL; Brown ST; Ling C; Shioda T; Muller WJ
    Mol Cell Biol; 2007 Dec; 27(24):8648-57. PubMed ID: 17938205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-224-5p targets EGR2 to promote the development of papillary thyroid carcinoma.
    Zang CS; Huang HT; Qiu J; Sun J; Ge RF; Jiang LW
    Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4890-4900. PubMed ID: 32432752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGR2 is elevated and positively regulates inflammatory IFNγ production in lupus CD4
    Dai R; Heid B; Xu X; Xie H; Reilly CM; Ahmed SA
    BMC Immunol; 2020 Jul; 21(1):41. PubMed ID: 32646370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reciprocal co-regulation of EGR2 and MECP2 is disrupted in Rett syndrome and autism.
    Swanberg SE; Nagarajan RP; Peddada S; Yasui DH; LaSalle JM
    Hum Mol Genet; 2009 Feb; 18(3):525-34. PubMed ID: 19000991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cord-Blood Natural Killer Cell-Based Immunotherapy for Cancer.
    Zhao X; Cai L; Hu Y; Wang H
    Front Immunol; 2020; 11():584099. PubMed ID: 33193399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.